Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REJOICE-PanTumor01: Raludotatug Deruxtecan in Advanced/Metastatic Solid Tumors
NCT06660654Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of raludotatug deruxtecan in solid tumor, endometrial cancer (EC), Cervical Cancer (CC) and 3 more (5 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective Response Rate up to 48 months, Disease Control Rate up to 48 months and 1 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
raludotatug deruxtecan
03
Conditions
solid tumorendometrial cancer (EC)Cervical Cancer (CC)ovarian cancerurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06660654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06660654.